Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) software

Journal of Nuclear Medicine

Volumn 45, Issue 8, 2004, Pages 1366-1372

  Sgouros, George ^a,c   Kolbert, Katherine S ^a   Sheikh, Arif ^a   Pentlow, Keith S ^a   Mun, Edward F ^a   Barth, Axel ^b   Robbins, Richard J ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3D internal dosimetry; 124I; Patient specific dosimetry; PET; Thyroid cancer

Indexed keywords

IODINE 124; IODINE 131; SODIUM IODIDE I 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG HALF LIFE; HUMAN; IMAGE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; THYROID CARCINOMA; ADENOCARCINOMA; ALGORITHM; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; EVALUATION; FEASIBILITY STUDY; METASTASIS; METHODOLOGY; PAPILLARY CARCINOMA; RADIATION DOSE; RADIOMETRY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; VALIDATION STUDY;

ADENOCARCINOMA, FOLLICULAR; ALGORITHMS; CARCINOMA, PAPILLARY; FEASIBILITY STUDIES; IMAGING, THREE-DIMENSIONAL; IODINE RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 4544236386     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281-296.
2. Pandit-Taskar N, Hamlin PA, Reyes S, Larson SM, Divgi CR. New strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep. 2003;5:364-371.
3. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003;30:31-38.
4. 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm. 2003;18:61-69.
5. Koral KF, Dewaraja Y, Li J, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in I-131-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44:457-464.
6. Descalle MA, Hartmann Siantar CL, Dauffy L, et al. Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy. Cancer Biother Radiopharm. 2003;18:71-79.
7. Flux GD, Guy MJ, Papavasileiou P, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 MIBG. Cancer Biother Radiopharm. 2003;18:81-87.
8. Ljungberg M, Frey E, Sjogreen K, et al. 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm. 2003;18:99-107.
9. Gardin I, Bouchet LG, Assie K, et al. Voxeldose: a computer program for 3-D dose calculation in therapeutic nuclear medicine. Cancer Biother Radiopharm. 2003;18:109-115.
10. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89-97.
11. Siantar CH, Vetter K, DeNardo GL, DeNardo SJ. Treatment planning for molecular targeted radionuclide therapy. Cancer Biother Radiopharm. 2002;17:267-280.
12. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
13. Sgouros G, Kolbert KS. The three-dimensional internal dosimetry software package, 3D-ID. In: Zaidi H, Sgouros G, eds. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine. Philadelphia, PA: Institute of Physics; 2002:249-258.
14. Ljungberg M, Dewaraja Y, Sgouros G, Strand SE. Evaluation and validation of dose calculation procedures in patient-specific radionuclide therapy. In: Zaidi H, Sgouros G, eds. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine. Philadelphia, PA: Institute of Physics; 2002:262-285.
15. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38:301-308.
16. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992;33:2020-2023.
17. Pentlow KS, Graham MC, Lambrecht RM, Cheung NK, Larson SM. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys. 1991;18:357-366.
18. Kolbert KS, Sgouros G, Scott AM, et al. Dose-volume histogram representation of patient dose distribution in 3-dimensional internal dosimetry. J Nucl Med. 1994;35:P123-P124.
19. Benua RS, Leeper RD. A method and rationale for treatment of thyroid carcinoma with the largest, safe dose of 131-I. In: Medeiros-Neto G, Gaitan E, eds. Frontiers in Thyroidology. New York, NY: Plenum Medical; 1986:1317-1321.
20. Benua RS, Rawson RW, Sonenberg M, Cicale NR. Relation of radioiodine dosimetry to results and complications in treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171-182.
21. Kolbert KS, Sgouros G. Display and manipulation of SPECT and CT studies for radiolabeled antibody therapy [abstract]. Cancer Biother Radiopharm. 1998;13:302.
22. Kolbert KS, Hamacher KA, Jurcic JG, et al. Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. J Nucl Med. 2001;42:27-32.
23. Furhang EE, Sgouros G, Chui CS. Radionuclide photon dose kernels for internal emitter dosimetry. Med Phys. 1996;23:759-764.
24. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80:2505-2509.
25. 131I following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718-722.
26. Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191-1195.
27. Yoshida K, Rivoire ML, Divgi CR, et al. Effect of tumor size on monoclonal antibody uptake in a metastatic model. J Surg Oncol. 1992;49:249-252.
28. Williams LE, Bares RB, Fass J, et al. Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass. Eur J Nucl Med. 1993;20:345-347.
29. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med. 1988;29:103-109.
30. Furhang EE, Chui CS, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys. 1997;24:1163-1172.
31. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
32. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
33. Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12:121-134.
34. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation-dose and outcome of radioiodine therapy for thyroid-cancer. N Engl J Med. 1983;309:937-941.
35. Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760-767.
36. Erdi YE, Macapinlac H, Larson SM, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging. 1999;2:41-46.
37. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes. II. Practical considerations in therapy and protection. AJR. 1948;59:260-281.
38. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.